Initial testing (stage 1) of tazemetostat (EPZ‐6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pediatric Blood & Cancer

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pbc.26218PMID 27555605PMCID PMC5584632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.

  2016cited by this paper
• The Expression of Cyclin D1, VEGF, EZH2, and H3K27me3 in Atypical Teratoid/Rhabdoid Tumors of the CNS: A Possible Role in Targeted Therapy

  2016cited by this paper
• Loss of BAP1 function leads to EZH2-dependent transformation

  2015cited by this paper
• Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors

  2015cited by this paper
• Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas

  2015cited by this paper
• 302 A phase 1 study of EPZ-6438 (E7438), an Enhancer of Zeste-Homolog 2 (EZH2) inhibitor: Preliminary activity in INI1-negative tumors

  2015cited by this paper
• Small molecule inhibitors of EZH2: the emerging translational landscape.

  2015cited by this paper
• ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2‐Inhibitors

  2015cited by this paper
• Abstract C87: EZH2 inhibition leads to decreased proliferation in SMARCA4-deleted ovarian cancer cell lines

  2015cited by this paper
• Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention

  2015cited by this paper
• Targeting of cancer stem cells by inhibitors of DNA and histone methylation

  2015cited by this paper
• EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity

  2015cited by this paper
• Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells

  2014cited by this paper
• Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

  2014cited by this paper
• EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors

  2014cited by this paper
• Epigenomic alterations define lethal CIMP-positive ependymomas of infancy

  2014cited by this paper
• Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas

  2014cited by this paper
• The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx)

  2014cited by this paper
• EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells

  2014cited by this paper
• Metronomic Docetaxel in PRINT Nanoparticles and EZH2 Silencing Have Synergistic Antitumor Effect in Ovarian Cancer

  2014cited by this paper
• Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

  2013cited by this paper
• Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.

  2013cited by this paper
• Histone H3.3 mutations: a variant path to cancer.

  2013cited by this paper
• The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation

  2012cited by this paper
• Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

  2012cited by this paper
• K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas

  2012cited by this paper
• Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

  2012cited by this paper
• EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

  2012cited by this paper
• Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

  2012cited by this paper
• Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.

  2011cited by this paper
• Frequent mutation of histone modifying genes in non-Hodgkin lymphoma

  2011cited by this paper
• Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

  2011cited by this paper
• EZH2 Y641 mutations in follicular lymphoma

  2011cited by this paper
• Aberrations of EZH2 in Cancer

  2011cited by this paper
• The Polycomb complex PRC2 and its mark in life

  2011cited by this paper
• Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

  2010cited by this paper
• Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation.

  2010cited by this paper
• Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin

  2010cited by this paper
• The pediatric preclinical testing program: Description of models and early testing results

  2007cited by this paper
• Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity

  2004cited by this paper

• Rhabdomyosarcoma: development of molecular therapeutics under the microscope

  2025cites this paper
• Nanopore Sequencing Reveals Novel Alternative Splice Variants of EZH2 in Pediatric Medulloblastoma

  2025cites this paper
• Synthetic lethality of EZH2 and DNMT Inhibition suppresses neuroblastoma proliferation via MYCN destabilization

  2025cites this paper
• Enhancing Triple-Negative Breast Cancer Radiotherapy via EZH2-Targeted Nanoplatform and Radionuclide Therapy.

  2025cites this paper
• Exploring the Role of Histone Lysine Methyl Transferases in Pancreatic Cancer: A Review of Therapeutics and Clinical Implications

  2025cites this paper
• SWI/SNF protein expression in anaplastic carcinomatous mural nodules of ovarian mucinous tumors.

  2025cites this paper
• Inhibiting EZH2 complements steroid effects in Duchenne muscular dystrophy

  2025cites this paper
• The Warburg effect: the hacked mitochondrial-nuclear communication in cancer.

  2025cites this paper
• Macromolecular interactions dictate Polycomb-mediated epigenetic repression

  2025cites this paper
• Aberrant histone modifications in pediatric brain tumors

  2025cites this paper
• Distinct specificity and functions of PRC2 subcomplexes in human stem cells and cardiac differentiation.

  2025cites this paper
• Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma

  2024cites this paper
• Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy

  2024cites this paper
• A framework for target discovery in rare cancers

  2024cites this paper
• Targeting histone methylation and demethylation for non-alcoholic fatty liver disease.

  2024cites this paper
• GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

  2024cites this paper
• Pharmacology and pharmacokinetics of tazemetostat

  2024cites this paper
• Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities

  2023cites this paper
• Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy

  2023cites this paper
• Advances in the Delivery and Development of Epigenetic Therapeutics for the Treatment of Cancer.

  2023cites this paper
• Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo.

  2023cites this paper
• Targeting EZH2 in SMARCB1-deficient sarcomas: advances and opportunities to potentiate the efficacy of EZH2 inhibitors.

  2023cites this paper
• An Epigenetic Insight Into the Gliomas

  2023cites this paper
• Children's Oncology Group's 2023 blueprint for research: Renal tumors

  2023cites this paper
• Tazemetostat for Tumors Harboring SMARCB1/SMARCA4 or EZH2 Alterations: Results from NCI-COG Pediatric MATCH APEC1621C.

  2023cites this paper
• EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer

  2023cites this paper
• (mis)-Targeting of SWI/SNF complex(es) in cancer

  2023cites this paper
• Distinct regulation of EZH2 and its repressive H3K27me3 mark in Polyomavirus -positive and -negative Merkel cell carcinoma.

  2023cites this paper
• Enhancer of zeste homolog 2 promotes renal fibrosis after acute kidney injury by inducing epithelial-mesenchymal transition and activation of M2 macrophage polarization

  2023cites this paper
• The roles of the SWI/SNF complex in cancer

  2023cites this paper
• Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2

  2022cites this paper
• Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies

  2022cites this paper
• Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors

  2022cites this paper
• Polycomb Directed Cell Fate Decisions in Development and Cancer

  2022cites this paper
• Poorly differentiated chordoma

  2022cites this paper
• Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumor.

  2022cites this paper
• CMAR_A_289544 479..498

  2022cites this paper
• Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors

  2022cites this paper
• Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies

  2021cites this paper
• Integration of epigenomics and metabolomics: From biomarkers discovery to personalized medicine

  2021cites this paper
• SMARCA4-Deficient Carcinoma of Uterine Cervix Resembling SCCOHT—Case Report

  2021cites this paper
• Going beyond Polycomb: EZH2 Functions in Prostate Cancer

  2021cites this paper
• Personalized Medicine for Neuroblastoma: Moving from Static Genotypes to Dynamic Simulations of Drug Response

  2021cites this paper
• Ilicicolin A Exerts Antitumor Effect in Castration-Resistant Prostate Cancer Via Suppressing EZH2 Signaling Pathway

  2021cites this paper
• Targeting EZH2 for the treatment of soft tissue sarcomas

  2021cites this paper
• Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells

  2021cites this paper
• Non‐rhabdomyosarcoma soft tissue sarcomas diagnosed in patients at a young age. An overview of clinical, pathological, and molecular findings

  2021cites this paper
• Cytomorphologic Spectrum of SMARCB1-Deficient Soft Tissue Neoplasms.

  2021cites this paper
• Progress Update in Pediatric Renal Tumors

  2021cites this paper
• YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer

  2020cites this paper
• Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis

  2020cites this paper
• Modeling medulloblastoma in vivo and with human cerebellar organoids

  2020cites this paper
• Advancing biology based therapeutic approaches for atypical teratoid rhabdoid tumors.

  2020cites this paper
• The SWI/SNF complex in cancer — biology, biomarkers and therapy

  2020cites this paper
• Invited Review: Dysregulation of chromatin remodellers in paediatric brain tumours – SMARCB1 and beyond

  2020cites this paper
• Local Stage dependent necessity of Radiotherapy in Rhabdoid Tumors of the Kidney (RTK) - the GPOH experience.

  2020cites this paper
• SWI/SNF complex-deficient soft tissue neoplasms: An update.

  2020cites this paper
• JNO special issue: an update on pediatric neuro-oncology

  2020cites this paper
• In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models—A report from the Pediatric Preclinical Testing Consortium

  2020cites this paper
• Primary SMARCA4-deficient undifferentiated sarcomatoid tumor of the gastroesophageal junction

  2020cites this paper
• Drug Development in Soft Tissue Sarcomas: Novel Targets and Recent Early Phase Trial Results.

  2020cites this paper
• Role of Polycomb Complexes in Normal and Malignant Plasma Cells

  2020cites this paper
• Improving TRAIL-induced apoptosis in cancers by interfering with histone modifications

  2020cites this paper
• Epigenetic modifications in acute lymphoblastic leukemia: From cellular mechanisms to therapeutics.

  2020cites this paper
• Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer

  2020cites this paper
• Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.

  2020cites this paper
• Epigenetics of Glioblastoma Multiforme: From Molecular Mechanisms to Therapeutic Approaches.

  2020cites this paper
• Histone methyl transferases: A class of epigenetic opportunities to counter uncontrolled cell proliferation.

  2019cites this paper
• Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation.

  2019cites this paper
• An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings

  2019cites this paper
• Novel therapy for pediatric and adolescent kidney cancer

  2019cites this paper
• Challenges and Opportunities for Childhood Cancer Drug Development

  2019cites this paper
• SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses

  2019cites this paper
• Comparison of the antineoplastic action of 3-deazaneplanocin-A and inhibitors that target the catalytic site of EZH2 histone methyltransferase

  2019cites this paper
• Atypical Teratoid Rhabdoid Tumors

  2019cites this paper
• RNA Interference Approaches and Assessment of New Delivery Systems to Target Heparanase in Soft-tissue Sarcomas

  2019cites this paper
• Pharmacoepigenetics: Basic Principles for Personalized Medicine

  2019cites this paper
• Coupling Fluorescence-Activated Cell Sorting and Targeted Analysis of Histone Modification Profiles in Primary Human Leukocytes

  2019cites this paper
• Diosgenin exhibits tumor suppressive function via down-regulation of EZH2 in pancreatic cancer cells

  2019cites this paper
• SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association

  2019cites this paper
• The Road to Pathogenesis: Charting the Development of LSCs and Pre-LSCs

  2019cites this paper
• Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies

  2019cites this paper
• EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.

  2019cites this paper
• Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.

  2018cites this paper
• Epigenetic Changes and Epigenetic Targets in Head and Neck Cancer

  2018cites this paper
• Etude de l'implication de mécanismes épigénétiques dans la physiopathologie du myélome multiple et dans la différenciation plasmocytaire normale

  2018cites this paper
• Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma

  2018cites this paper
• Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis

  2018cites this paper
• Potential Epigenetic-Based Therapeutic Targets for Glioma

  2018cites this paper
• PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

  2018cites this paper
• Embryonal Tumors of the Central Nervous System in Children: The Era of Targeted Therapeutics

  2018cites this paper
• Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.

  2018cites this paper
• [EZH2 is therapeutic target for personalized treatment in multiple myeloma].

  2018cites this paper
• Cancer epigenetics: Moving forward

  2018cites this paper
• High‐dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survival—The Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) experience

  2018cites this paper
• Emerging therapeutic targets for the treatment of malignant rhabdoid tumors

  2018cites this paper
• Clinicopathologic characteristics of poorly differentiated chordoma

  2018cites this paper
• Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia

  2018cites this paper
• EZH2 upregulation correlates with tumor invasiveness, proliferation, and angiogenesis in human pituitary adenomas.

  2017cites this paper
• Structure, mechanism, and regulation of polycomb-repressive complex 2

  2017cites this paper